- Apotex has commercially launched Apo-Semaglutide Injection, a generic equivalent of Ozempic, with shipments already underway to wholesalers and pharmacy availability expected across Canada in the coming weeks
- The once-weekly treatment for adults with type 2 diabetes is available in both 2 mg and 4 mg prefilled pen formats, supporting 0.25 mg, 0.5 mg, and 1 mg dosing options aligned with all brand-equivalent formats
- Developed in partnership with Orbicular Pharmaceutical Technologies, the product uses a prefilled pen designed to mirror the brand-name semaglutide experience, helping support familiarity and smoother transitions for patients and healthcare professionals
- Apotex said the launch reinforces its long-standing focus on expanding access to high-quality, affordable medicines while supporting the sustainability of Canada’s healthcare system
Takeaways
Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and employer plans that prioritize lower‑cost options.
Because Apotex is the first Canadian company with a generic and can match the key 2 mg and 4 mg pen formats, it is well placed to win share via tenders and formulary listings, while also nudging broader GLP‑1 access by making semaglutide more affordable for type 2 diabetes, and indirectly supporting continued off‑label weight‑management use where payers allow it.
Source: PRnewswire
